

Tenascin-C-Derived Peptide, TNIIIA2

Subjects: [Biochemistry & Molecular Biology](#)

Contributor: Motomichi Fujita , Manabu Sasada , Takuya Iyoda , Fumio Fukai

Matricellular proteins harbor functional sites within their molecular structures. These functional sites are released via proteolytic cleavage by inflammatory proteinases, and the peptides containing these hidden functional sites have unique biological activities that are often not detected in the parent molecules. A peptide containing the functional site of tenascin-C (TNC), termed TNIIIA2, which is highly released at sites of inflammation and in the tumor microenvironment, has the ability to potently and persistently activate β 1-integrins. Based on these activities, TNIIIA2-containing TNC fragments/peptides are involved in the acquisition of aggressiveness in cancer progression.

Tenascin-C

TNIIIA2

β 1-integrin

integrin activation

matricellular protein

platelet-derived growth factor

matricryptic site

matricryptin

1. Instructions

Tenascin-C (TNC) is a multifunctional glycoprotein that belongs to a family of matricellular proteins ^[1]. It is highly expressed during embryonic development, but its expression levels rapidly decrease and are limited in normal adult tissues ^[1]. TNC is strongly re-expressed in particular environments such as inflammatory regions ^[2], tissue remodeling ^{[3][4][5]}, and the tumor microenvironment (TME) ^[6], indicating a close association with pathogenesis. A high expression of TNC has been observed in various cancers including pancreatic cancer ^[7], gastric cancer ^[8], colorectal cancer ^[9], esophageal adenocarcinoma ^[10], lung cancer ^[11], breast cancer ^[12], and glioma/glioblastoma ^{[6][13]}. High TNC levels are correlated with poor prognosis in patients with various types of cancer, and its expression is therefore considered a poor prognostic factor. Besides cancer cells, other cells in the TME including fibroblasts, endothelial cells, and macrophages express TNC, thus contributing to cancer aggression ^{[14][15]}.

2. Development

TNC has been shown to have both proadhesive and antiadhesive properties in a context-dependent manner ^[1]. These underlying mechanisms remain elusive but could be explained in terms of the considerable diversity of TNC's molecular forms. As shown in [Figure 1A](#), TNC is composed of a central domain (assembly domain), epidermal growth factor (EGF)-like repeats, fibronectin (FN) type III-like domains, and a fibrinogen globe-like domain, which are capable of interaction with extracellular matrix (ECM) proteins, soluble factors, and cell receptors ^[6]. Moreover, human TNC contains 9 alternative splicing repeats in FN type III-like domains, and alternative splicing theoretically generates 511 possible splice variants ^[1], thus leading to the expression of TNC's

multifunctional activities in a context-dependent manner [6]. ECM remodeling often occurs in the TME and inflammatory regions where bioactive functions are released via cleavage by inflammatory proteinases [16]. TNC can also be proteolytically processed by matrix metalloproteinases (MMP) a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS), and alternative splicing repeats within FN type III repeats are particularly cleaved by MMP, which in turn exposes the specific bioactivity of TNC [1][16]. Among the TNC variants, those containing the FN type III repeats A2 are highly expressed in malignancies [17]. Saito et al. previously found that FN type III repeats A2 of TNC molecules have cryptic sites composed of the amino acid sequence YTITIRGV (Figure 1A). Moreover, the 22-mer peptide TNIIIA2 containing its functional sites can induce the activation of integrin $\alpha 5 \beta 1$ through a lateral association with transmembrane heparan sulfate proteoglycan syndecan-4 (Figure 1B,C), which leads to the induction and potentiation of cell adhesion to the ECM [18]. This TNIIIA2-induced integrin activation is more potent and persistent than other known integrin activators [19]. Based on these effects, peptide TNIIIA2 was shown to influence various cellular functions[20][21][22][23][24][25][26][27][28]. Among them, the action of TNIIIA2 on survival and proliferation in stromal cells are interesting with regard to involvement in cancer progression. Peptide TNIIIA2 rendered NIH3T3 mouse nontransformed fibroblasts anoikis-resistant through integrin $\alpha 5 \beta 1$ activation-mediated prosurvival signaling [19]. Peptide TNIIIA2 also induced the platelet-derived growth factor (PDGF)-dependent dimerization of PDGF receptor (PDGF-R) β via the activation of integrin $\alpha 5 \beta 1$ to promote the PDGF-R β /Ras/mitogen-activated protein kinase (MAPK) signaling pathway, followed by the induction of hyperproliferation and the formation of dense multilayered cell aggregates—that is, transformed foci in NIH3T3 cells (Figure 2) [19]. These results suggest that TNIIIA2 has the ability to disrupt the normal cell phenotype. This raises the possibility that TNIIIA2-containing TNC fragments/peptides might be involved in oncogenic transformation and malignant progression[24][25][26][27][28].




Figure 1. Tenascin-C (TNC)-derived TNIIIA2 fragments/peptides. (A) Schematic illustration of TNC and amino acid sequence of proadhesive peptide TNIIIA2. (B) Conformational shift of integrin activation by peptide TNIIIA2. (C)

Lateral interaction of integrin with syndecan-4 ectodomain by peptide TNIIIA2.




Figure 2. Physical and functional association between TNIIIA2-stimulated integrin $\alpha 5 \beta 1$ and PDGF receptor (PDGF-R). Peptide TNIIIA2 induces integrin $\alpha 5 \beta 1$ activation through a lateral association with syndecan-4, facilitating the formation of a molecular complex that includes activated integrin $\alpha 5 \beta 1$, syndecan-4, and activated PDGF-R in cholesterol- and caveolin-enriched membrane microdomains, which results in an enhanced activation of PDGF-R and leads to the hyperstimulation of cell proliferation.

References

1. Sean P Giblin; Kim S Midwood; Tenascin-C: Form versus function. *Cell Adhesion & Migration* **2014**, 9, 48-82, 10.4161/19336918.2014.987587.
2. Kim S Midwood; Sandra Sacre; Anna Maria Piccinini; Julia Inglis; Annette Trebault; Emma Chan; Stefan Drexler; Nidhi Sofat; Masahide Kashiwagi; Gertraud Orend; et al. Fionula Brennan Brian Foxwell Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. *Nature Medicine* **2009**, 15, 774-780, 10.1038/nm.1987.

3. Hidenori Suzuki; Masashi Fujimoto; Fumihiro Kawakita; Lei Liu; Fumi Nakano; Hirofumi Nishikawa; Takeshi Okada; Kyoko Imanaka-Yoshida; Toshimichi Yoshida; Masato Shiba; et al. Toll-Like Receptor 4 and Tenascin-C Signaling in Cerebral Vasospasm and Brain Injuries After Subarachnoid Hemorrhage.. *Acta Neurochirurgica Supplement* **2020**, *127*, 91-96, 10.1007/978-3-030-04615-6_15.
4. Taizo Kimura; Kazuko Tajiri; Akira Sato; Satoshi Sakai; Zheng Wang; Toshimichi Yoshida; Toshimitsu Uede; Michiaki Hiroe; Kazutaka Aonuma; Masaki Ieda; et al. Kyoko Imanaka-Yoshida Tenascin-C accelerates adverse ventricular remodelling after myocardial infarction by modulating macrophage polarization. *Cardiovascular Research* **2018**, *115*, 614-624, 10.1093/cvr/cvy244.
5. Swati Bhattacharyya; Wenxia Wang; Luisa Morales-Nebreda; Gang Feng; Minghua Wu; Xiaodong Zhou; Robert Lafyatis; Jungwha Lee; Monique Hinchcliff; Carol Feghali-Bostwick; et al. Katja Lakota G. R. Scott Budinger Kirtee Raparia Zenshiro Tamaki John Varga Tenascin-C drives persistence of organ fibrosis. *Nature Communications* **2016**, *7*, 11703, 10.1038/ncomms11703.
6. Kim S. Midwood; Thomas Hussenet; Benoit Langlois; Gertraud Orend; Advances in tenascin-C biology. *Cellular and Molecular Life Sciences* **2011**, *68*, 3175-3199, 10.1007/s00018-011-0783-6.
7. Joni Leppänen; Ville Lindholm; Joel Isohookana; Kirsi-Maria Haapasaari; Peeter Karihtala; Petri P. Lehenkari; Juha Saarnio; Joonas H Kauppila; Tuomo J. Karttunen; Olli Helminen; et al. Heikki Huhta Tenascin C, Fibronectin, and Tumor-Stroma Ratio in Pancreatic Ductal Adenocarcinoma. *Pancreas* **2019**, *48*, 43-48, 10.1097/mpa.0000000000001195.
8. Wenbo Qi; Zhaoting Yang; Haoyue Li; Yan Cui; Yanhua Xuan; The role of Tenascin-C and Twist1 in gastric cancer: cancer progression and prognosis. *APMIS* **2019**, *127*, 64-71, 10.1111/apm.12919.
9. Tomohiro Murakami; Hirotoshi Kikuchi; Hisato Ishimatsu; Ichirota Iino; Amane Hirotsu; Tomohiro Matsumoto; Yusuke Ozaki; Toshiki Kawabata; Yoshihiro Hiramatsu; Manabu Ohta; et al. Kinji Kamiya Mayu Fukushima Satoshi Baba Kyoko Kitagawa Masatoshi Kitagawa Hiroyuki Konno Tenascin C in colorectal cancer stroma is a predictive marker for liver metastasis and is a potent target of miR-198 as identified by microRNA analysis. *British Journal of Cancer* **2017**, *117*, 1360-1370, 10.1038/bjc.2017.291.
10. Zhao-Ting Yang; So-Young Yeo; Yong-Xue Yin; Zhen-Hua Lin; Hak-Min Lee; Yan-Hua Xuan; Yan Cui; Seok-Hyung Kim; Tenascin-C, a Prognostic Determinant of Esophageal Squamous Cell Carcinoma. *PLOS ONE* **2016**, *11*, e0145807, 10.1371/journal.pone.0145807.
11. Vasilena Gocheva; Alexandra Naba; Arjun Bhutkar; Talia Guardia; Kathryn M. Miller; Carman Man-Chung Li; Talya L. Dayton; Francisco J. Sánchez-Rivera; Caroline Kim-Kiselak; Noor Jailkhani; et al. Monte M Winslow Amanda Del Rosario Richard O. Hynes Tyler Jacks Quantitative proteomics identify Tenascin-C as a promoter of lung cancer progression and contributor to a

- signature prognostic of patient survival.. *Proceedings of the National Academy of Sciences* **2017**, *114*, E5625-E5634, 10.1073/pnas.1707054114.
12. A Ishihara; T Yoshida; H Tamaki; T Sakakura; Tenascin expression in cancer cells and stroma of human breast cancer and its prognostic significance.. *Clinical Cancer Research* **1995**, *1*, 1035-41.
 13. J. Qi; Darian R. Esfahani; T. Huang; Patrick A. Ozark; Elizabeth T. Bartom; Rintaro Hashizume; Erin R. Bonner; S. An; Craig Horbinski; C. David James; et al.A. M. Saratsis Tenascin-C expression contributes to pediatric brainstem glioma tumor phenotype and represents a novel biomarker of disease. *Acta Neuropathologica Communications* **2019**, *7*, 75, 10.1186/s40478-019-0727-1.
 14. Anna Mary Steitz; Alina Steffes; Florian Finkernagel; Annika Unger; Leah Sommerfeld; Julia M. Jansen; Uwe Wagner; Johannes Graumann; Rolf Müller; Silke Reinartz; et al. Tumor-associated macrophages promote ovarian cancer cell migration by secreting transforming growth factor beta induced (TGFB1) and tenascin C. *Cell Death & Disease* **2020**, *11*, 1-15, 10.1038/s41419-020-2438-8.
 15. Pablo Igor Ribeiro Franco; Arthur Perillo Rodrigues; Liliana Borges De Menezes; Marina Pacheco Miguel; Pablo Igor Ribeiro Franco; Liliana Borges De Menezes Leite; Tumor microenvironment components: Allies of cancer progression. *Pathology - Research and Practice* **2020**, *216*, 152729, 10.1016/j.prp.2019.152729.
 16. Kim S. Midwood; Matthias Chiquet; Richard P. Tucker; Gertraud Orend; Tenascin-C at a glance. *Journal of Cell Science* **2016**, *129*, 4321-4327, 10.1242/jcs.190546.
 17. Margret Dueck; Stefan Riedl; Ulf Hinz; Andrea Tandara; Christian Herfarth; Andreas Faissner; Detection of tenascin-C isoforms in colorectal mucosa, ulcerative colitis, carcinomas and liver metastases. *International Journal of Cancer* **1999**, *82*, 477-483, 10.1002/(sici)1097-0215(19990812)82:43.0.co;2-5.
 18. Yohei Saito; Hisae Imazeki; Shogo Miura; Tomohisa Yoshimura; Hiroaki Okutsu; Yosei Harada; Toshiyuki Ohwaki; Osamu Nagao; Sadahiro Kamiya; Ryo Hayashi; et al.Hiroaki KodamaHiroshi HandaToshimichi YoshidaFumio Fukai A Peptide Derived from Tenascin-C Induces β 1 Integrin Activation through Syndecan-4. *Journal of Biological Chemistry* **2007**, *282*, 34929-34937, 10.1074/jbc.m705608200.
 19. Rika Tanaka; Yutaka Seki; Yohei Saito; Sadahiro Kamiya; Motomichi Fujita; Hiroaki Okutsu; Takuya Iyoda; Tatsuya Takai; Toshiyuki Owaki; Hirofumi Yajima; et al.Junichi TairaRyo HayashiHiroaki KodamaTakuya MatsunagaFumio Fukai Tenascin-C-derived Peptide TNIIIA2 Highly Enhances Cell Survival and Platelet-derived Growth Factor (PDGF)-dependent Cell Proliferation through Potentiated and Sustained Activation of Integrin α 5 β 1. *Journal of Biological Chemistry* **2014**, *289*, 17699-17708, 10.1074/jbc.m113.546622.

20. Rika Tanaka; Toshiyuki Owaki; Sadahiro Kamiya; Takuya Matsunaga; Kazuya Shimoda; Hiroaki Kodama; Ryo Hayashi; Takashi Abe; Yosei P. Harada; Motoyuki Shimonaka; et al. Hirofumi Yajima Hiroshi Terada Fumio Fukai VLA-5-mediated Adhesion to Fibronectin Accelerates Hemin-stimulated Erythroid Differentiation of K562 Cells through Induction of VLA-4 Expression. *Journal of Biological Chemistry* **2009**, 284, 19817-19825, 10.1074/jbc.m109.009860.
21. Yohei Saito; Toshiyuki Owaki; Takuya Matsunaga; Mizue Saze; Shogo Miura; Mao Maeda; Mayu Eguchi; Rika Tanaka; Junichi Taira; Hiroaki Kodama; et al. Sumio Goto Yoshiroh Niitsu Hiroshi Terada Fumio Fukai Apoptotic Death of Hematopoietic Tumor Cells through Potentiated and Sustained Adhesion to Fibronectin via VLA-4. *Journal of Biological Chemistry* **2009**, 285, 7006-7015, 10.1074/jbc.m109.027581.
22. Kazuki Otsuka; Manabu Sasada; Takuya Iyoda; Yusuke Nohara; Shunsuke Sakai; Tatsufumi Asayama; Yusuke Suenaga; Sana Yokoi; Yoshikazu Higami; Hiroaki Kodama; et al. Fumio Fukai Combining peptide TNIIIA2 with all-trans retinoic acid accelerates N-Myc protein degradation and neuronal differentiation in MYCN-amplified neuroblastoma cells.. *American journal of cancer research* **2019**, 9, 434-448.
23. Kazuki Otsuka; Manabu Sasada; Y U Hirano; Yusuke Nohara; Takuya Iyoda; Yoshikazu Higami; Hiroaki Kodama; Fumio Fukai; Acyclic Retinoid Combined With Tenascin-C-derived Peptide Reduces the Malignant Phenotype of Neuroblastoma Cells Through N-Myc Degradation.. *Anticancer Research* **2019**, 39, 3487-3492, 10.21873/anticanres.13494.
24. Motomichi Fujita; Tetsuya Yamamoto; Takuya Iyoda; Tatsuya Fujisawa; Manabu Sasada; Reo Nagai; Chikako Kudo; Kazuki Otsuka; Sadahiro Kamiya; Hiroaki Kodama; et al. Fumio Fukai Aggressive Progression in Glioblastoma Cells through Potentiated Activation of Integrin $\alpha 5 \beta 1$ by the Tenascin-C-Derived Peptide TNIIIA2.. *Molecular Cancer Therapeutics* **2019**, 18, 1649-1658, 10.1158/1535-7163.MCT-18-1251.
25. Motomichi Fujita; Tetsuya Yamamoto; Takuya Iyoda; Tatsuya Fujisawa; Reo Nagai; Chikako Kudo; Manabu Sasada; Hiroaki Kodama; Fumio Fukai; Autocrine Production of PDGF Stimulated by the Tenascin-C-Derived Peptide TNIIIA2 Induces Hyper-Proliferation in Glioblastoma Cells.. *International Journal of Molecular Sciences* **2019**, 20, 3183, 10.3390/ijms20133183.
26. Motomichi Fujita; Yuka Ito-Fujita; Takuya Iyoda; Manabu Sasada; Yuko Okada; Kazuma Ishibashi; Takuro Osawa; Hiroaki Kodama; Fumio Fukai; Hideo Suzuki; et al. Peptide TNIIIA2 Derived from Tenascin-C Contributes to Malignant Progression in Colitis-Associated Colorectal Cancer via $\beta 1$ -Integrin Activation in Fibroblasts.. *International Journal of Molecular Sciences* **2019**, 20, 2752, 10.3390/ijms20112752.
27. Hideo Suzuki; Manabu Sasada; Sadahiro Kamiya; Yuka Ito; Hikaru Watanabe; Yuko Okada; Kazuma Ishibashi; Takuya Iyoda; Akinori Yanaka; Fumio Fukai; et al. The Promoting Effect of the

Extracellular Matrix Peptide TNIIIA2 Derived from Tenascin-C in Colon Cancer Cell Infiltration. *International Journal of Molecular Sciences* **2017**, *18*, 181, 10.3390/ijms18010181.

28. Motomichi Fujita; Manabu Sasada; Takuya Iyoda; Fumio Fukai; Involvement of Integrin-Activating Peptides Derived from Tenascin-C in Cancer Aggression and New Anticancer Strategy Using the Fibronectin-Derived Integrin-Inactivating Peptide. *Molecules* **2020**, *25*, 3239, 10.3390/molecules25143239.
-

Retrieved from <https://www.encyclopedia.pub/entry/history/show/9333>